Sector News

J&J set to reopen McNeil plant amid consumer biz overhaul

July 15, 2015
Life sciences
Johnson & Johnson has worked hard the last 5 years to revamp its consumer healthcare business after serious quality issues at some of its plants marred its once-stellar reputation, forcing it to issue a series of recalls and pull products from retailers’ shelves. But the company is moving closer to resolving its consumer healthcare woes, preparing to reopen a Philadelphia-area factory that was once at the center of the drama.
 
J&J recently had a positive FDA inspection at its Fort Washington, PA-based McNeil Consumer Healthcare plant and is waiting for final word from the agency, Sandra Peterson, head of the company’s consumer healthcare business, said in J&J’s Q2 earnings call. The company closed the facility in 2010 after recalling more than 135 million medicine products when customers found tiny metal particles in children’s Tylenol and other problems. Instead of laying out an action plan to address the issues when they surfaced, officials turned a blind eye and did not take required actions until regulators came to investigate.
 
As a result, J&J was forced to implement a series of changes, including signing an FDA consent decree over its McNeil plant in 2011, shelling out more than $100 million to upgrade the facility and pulling a number of its consumer products–a move that cost the company billions in sales. Earlier this year it pleaded guilty to a federal misdemeanor charge that sprang from the troubles and paid $25 million in penalties.
 
But J&J has “made a lot of progress,” since then, CEO Alex Gorsky told investors in the company’s Q2 earnings call. The FDA has already signed off on two other manufacturing plants in Las Piedras, Puerto Rico, and Lancaster, PA, that were once scrutinized by the agency. And about 80% of recalled brands are back on the market, Peterson added.
 
Gorsky brought on Peterson in 2012 to retool J&J’s consumer healthcare business, and she has not wasted any time cleaning up shop since then. The company has relaunched its U.S. OTC business, Peterson noted in the company’s Q2 earnings call, and is rolling out new products to ramp up sales. J&J’s hard work seems to be paying off, as consumer sales grew 4% during the first half.
 
“Our consumer expertise and insight are highly valuable to payers and providers, which differentiates us from our competitors,” Peterson said. “We view a healthy consumer business as a growth annuity for J&J with less volatility than other markets.”
 
And the company could use the extra boost from its consumer unit as it counters less-than-stellar Q2 results for its pharma business. J&J’s second quarter pharma sales fell by 7.9%, and its top line only increased by 1.7%. Increased competition to its hep C drug Olysio is partly to blame, the company said, as products from Gilead Sciences and AbbVie gobble up market share.
 
By Emily Wasserman
 

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.